Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Unusually active option classes on open September 25th
- Strategic Growth and Unique Positioning Drive Buy Rating for Recursion Pharmaceuticals
- Recursion Pharmaceuticals management to meet with Needham
- Buy Recommendation for Recursion Pharmaceuticals: Strong Position in AI-Driven Drug Discovery with Strategic Acquisitions and Financial Stability
- Private Markets: Anthropic raises $13B Series F at $183B post-money valuation